
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HS6ST1 CRISPR/Cas9 KO Plasmid (h) | sc-405111 | 20 µg | $397.00 |
HS6ST1 encodes heparan sulfate 6-O-sulfotransferase 1, a Golgi-resident enzyme that catalyzes 6-O-sulfation of glucosamine residues during heparan sulfate proteoglycan maturation. This modification shapes heparan sulfate binding sites that control the distribution and signaling potency of multiple morphogens and growth factors, influencing processes such as receptor tyrosine kinase signaling, cell–matrix interactions, and developmental patterning. By tuning heparan sulfate fine structure, HS6ST1 can modulate pathways including FGF, WNT, BMP, and Hedgehog signaling in a context-dependent manner. Altered heparan sulfate sulfation programs involving HS6ST1 have been associated with dysregulated cellular communication in cancer biology and neurodevelopmental phenotypes, making it a useful node for mechanistic studies of extracellular signaling regulation.
HS6ST1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HS6ST1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HS6ST1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HS6ST1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HS6ST1 protein expression.
This CRISPR knockout system enables efficient generation of HS6ST1-deficient cell models for investigation of HS6ST1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.